Potential of Three Ethnomedicinal Plants as Antisickling Agents
- PMID: 28043127
- PMCID: PMC5963525
- DOI: 10.1021/acs.molpharmaceut.6b00767
Potential of Three Ethnomedicinal Plants as Antisickling Agents
Abstract
Sickle cell disease (SCD) is a genetic blood disorder that affects the shape and transportation of red blood cells (RBCs) in blood vessels, leading to various clinical complications. Many drugs that are available for treating the disease are insufficiently effective, toxic, or too expensive. Therefore, there is a pressing need for safe, effective, and inexpensive therapeutic agents from indigenous plants used in ethnomedicines. The potential of aqueous extracts of Cajanus cajan leaf and seed, Zanthoxylum zanthoxyloides leaf, and Carica papaya leaf in sickle cell disease management was investigated in vitro using freshly prepared 2% sodium metabisulfite for sickling induction. The results indicated that the percentage of sickled cells, which was initially 91.6% in the control, was reduced to 29.3%, 41.7%, 32.8%, 38.2%, 47.6%, in the presence of hydroxyurea, C. cajan seed, C. cajan leaf, Z. zanthoxyloides leaf, and C. papaya leaf extracts, respectively, where the rate of polymerization inhibition was 6.5, 5.9, 8.0, 6.6, and 6.0 (×10-2) accordingly. It was also found that the RBC resistance to hemolysis was increased in the presence of the tested agents as indicated by the reduction of the percentage of hemolyzed cells from 100% to 0%. The phytochemical screening results indicated the presence of important phytochemicals including tannins, saponins, alkaloids, flavonoids, and glycosides in all the plant extracts. Finally, gas chromatography-mass spectrometry analysis showed the presence of important secondary metabolites in the plants. These results suggest that the plant extracts have some potential to be used as alternative antisickling therapy to hydroxyurea in SCD management.
Keywords: antisickling; drug discovery; medicinal plants; secondary metabolites; sickle cell disease.
Conflict of interest statement
The authors declare no competing financial interest.
Figures
References
-
- Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180(4581):326–8. - PubMed
-
- Ahrens T, Rutherford K, Basham KAR. Essentials of oxygenation: implication for clinical practice. Jones & Bartlett Learning; 1993.
-
- Voet D, Voet JG, Pratt CW. Fundamentals of Biochemistry. John Wiley & Sons, Inc; 1999.
-
- Basset P, Braconnier F, Rosa J. An update on electrophoretic and chromatographic methods in the diagnosis of hemoglobinopathies. J Chromatogr, Biomed Appl. 1982;227(2):267–304. - PubMed
-
- Geller AK, O’Connor MK. The sickle cell crisis: a dilemma in pain relief. Mayo Clin Proc. 2008;83(3):320–323. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
